Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders - Wikidata - awgldk - TriplyDB

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

http://www.wikidata.org/entity/Q37143117

about

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder Getting the balance right: Established and emerging therapies for major depressive disorders Rapid antidepressant effects: moving right along Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Stress as a one-armed bandit: Differential effects of stress paradigms on the morphology, neurochemistry and behavior in the rodent amygdala.Zinc in the Glutamatergic Theory of Depression The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission A review of MR spectroscopy studies of pediatric bipolar disorder The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Clinical and molecular genetics of psychotic depression Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Ketamine for treatment-resistant unipolar depression: current evidence Cell atrophy and loss in depression: reversal by antidepressant treatment Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms 50 years of hurdles and hope in anxiolytic drug discovery Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice Chronic Treatment with the IDO1 Inhibitor 1-Methyl-D-Tryptophan Minimizes the Behavioural and Biochemical Abnormalities Induced by Unpredictable Chronic Mild Stress in Mice - Comparison with Fluoxetine Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment New therapeutic targets for mood disorders Genome-wide association scan of trait depression Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health.Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine New frontiers in animal research of psychiatric illness Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour.Acute D-serine treatment produces antidepressant-like effects in rodents Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice.Socially responsive effects of brain oxidative metabolism on aggression.The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications.Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.From synapse to nucleus: novel targets for treating depression.Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.The association of interoceptive awareness and alexithymia with neurotransmitter concentrations in insula and anterior cingulate

P2860

Q24602988-E3814EFF-57F6-4543-99F3-9CBFBC066D18 Q24610225-FA6834DE-A25E-4FE8-8FD3-22EC445F0132 Q24614410-88FE4BDB-1C3E-4ECC-A7E6-078A15F2A23A Q24629398-382B691F-6E7C-4C78-B46F-AA329D3BD1FB Q24630153-C4958296-B872-4CF2-8530-DB577636ABCF Q24632936-C3EB7DCF-3AAC-4428-810D-606B6D8D3F7C Q26769043-2380AAA6-D784-4388-A0CE-2551283A79E5 Q26786214-CD97B65B-66F5-4AF8-B4EB-FFC31A6619DF Q26859198-359560E7-9DFA-4A88-BEEE-F910DD790D8A Q26991430-EF05D64D-6357-474E-9AE0-83A60C3BD4F7 Q26998975-73A9F55E-D588-41D9-8941-B5E8F8DAC497 Q27004154-5E7F121A-07B4-4504-8A84-1DC6A3C64403 Q27004490-46D53555-DB24-40FE-9AFC-C154C3421DD0 Q27004508-25AC9E74-5063-4A13-8F41-AD2611ABEF3C Q27013609-FAF68FFF-1CDF-481C-8180-21C0423C7C26 Q28073684-250A0DC4-F715-49E0-B655-F5AD3AA538BF Q28297569-7DD67D95-44FC-452F-83FB-8CB49A420608 Q28472408-44638471-3459-43BE-9EAA-D661393C0FD1 Q28484157-D0356B95-3C9D-4307-9706-B4F9EFFD1E8A Q28485938-73E071BA-FBB2-4FAC-B29A-4A2F1CA0C96D Q28553299-DA455A87-C143-4AF8-BCF9-1275AF5FC2D1 Q28729135-8027B680-44E2-4102-8E87-C697E5465B08 Q28743068-6DDF1C32-1CEE-4E47-91FA-6B8CA65F58AB Q28943415-6DF6308A-98AE-4871-AD32-F84CC5332C5D Q30457438-CDAF5C4B-1A7E-40E6-90F3-BE924DEB0532 Q30458884-0177216B-8F20-4377-87F6-1A17F7F0D0A5 Q30468290-33490777-151F-4637-A07D-737F96558D03 Q30478314-665E76BA-C8FC-4F0A-92DD-421E3A232388 Q30505292-C2CAC7DC-A06F-4CC3-A0F4-554B4440DD21 Q30508512-4BBC116D-4446-4160-A801-8E2422F0D6A7 Q30538101-FAE3FECE-1C79-485B-BC6C-C5D40A06E0AA Q30540124-24FD9AA6-FB46-466A-AC18-A0F22A9EFB5A Q30586804-4227E929-6702-43EF-8BB6-EC4FE38C4CB2 Q30987811-640A24AD-2F28-47BB-8193-11F3DBF79FC5 Q31141746-A6FD3E13-C422-4837-9349-32592A0EA255 Q33389974-68B14EDE-86CA-4F75-B86B-D703A3F5B187 Q33604879-4EC1B39E-8B2B-4335-8A93-CAE88C76A7D3 Q33653177-3073B544-7526-462C-A9F5-47069D8AA5CC Q33678656-2E188EB5-C7FC-4154-B677-3349257BF0AA Q33692296-2C0F6B28-E0C1-4AF6-84F7-106BA1F66895

P2860

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

http://www.wikidata.org/entity/Q37143117

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the glutamatergic sy ...... herapeutics for mood disorders

@en

Targeting the glutamatergic sy ...... erapeutics for mood disorders.

@nl

type

label

Targeting the glutamatergic sy ...... herapeutics for mood disorders

@en

Targeting the glutamatergic sy ...... erapeutics for mood disorders.

@nl

prefLabel

Targeting the glutamatergic sy ...... herapeutics for mood disorders

@en

Targeting the glutamatergic sy ...... erapeutics for mood disorders.

@nl

P1433

Q37143117-4775543C-3740-4386-A475-28A2E91A3FF1

P1476

Q37143117-5268B78B-8976-4220-87C4-5B6F49AD0E2C

P2093

Q37143117-225E60E7-296E-4505-8842-37EDD0047EF2

Q37143117-3136159C-79E3-4209-8B40-CF642A462AEA

Q37143117-751F50C2-9647-4CD2-BFAC-2232800A5DE7

Q37143117-C8062F99-1F9B-4CFD-AC1F-D02A0B1D73E8

P2860

Q37143117-0197E23D-27B9-4877-8C85-4B451F3E6732

Q37143117-02B48CB0-672F-413B-B52D-1407F3F5E3E6

Q37143117-05100C28-0CD7-43E9-9F91-804F61FEEA37

Q37143117-0876EEBB-0B37-4299-9393-9585612631B2

Q37143117-087A88E7-FA97-4639-995A-B5CBE7C0DE60

Q37143117-092FA4AA-95C7-4BFA-A341-434BCF71A5C7

Q37143117-0A713410-6CBC-4B36-A25D-639A6A0B2F5B

Q37143117-0D1CA12D-6DF7-4875-B1EA-F2ABDDB6E21B

Q37143117-0F4D3FCD-1D33-46EA-99F4-27A154A00C49

Q37143117-103A830F-7D24-4F00-B887-AAF2E1BF19F4

P2888

Q37143117-6C847940-361E-49BD-BA6F-E030D73D948E

P304

Q37143117-288CA209-0490-4E78-8075-34C511FFB795

P31

Q37143117-CFF7EBBB-F221-4B57-BA24-9F447804AF38

P356

Q37143117-864A1C93-DFE3-4D5C-82A4-B256B2C74DAB

P433

Q37143117-DE9CEA6E-8B2B-4285-A8F0-4DA550F8AB9D

P478

Q37143117-D634F96A-1C63-48CE-BF59-B0A9DB5AC68C

P577

Q37143117-EF56B595-2299-4389-BE7C-18B43AA1EF0E

P5875

Q37143117-E7869887-5D35-4445-A17C-4E09C191939F

P698

Q37143117-87E05286-7B26-427E-B403-4E427FF6E3C3

P932

Q37143117-2E980B48-33A9-4993-8F7A-EDD855928F3E

P356

P1433

Nature Reviews Drug Discovery

P1476

Targeting the glutamatergic sy ...... herapeutics for mood disorders

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Gerard Sanacora

http://www.w3.org/2001/XMLSchema#string

Husseini K Manji

http://www.w3.org/2001/XMLSchema#string

John H Krystal

http://www.w3.org/2001/XMLSchema#string

P2860

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex

Chronic elevation of brain-derived neurotrophic factor by ampakines

Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia

Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry

The role of dopamine in the pathophysiology of depression

P2888

P304

426-437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2462

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5427817

http://www.w3.org/2001/XMLSchema#string

P698

18425072

http://www.w3.org/2001/XMLSchema#string

P932

2715836

http://www.w3.org/2001/XMLSchema#string